Oncolytics Biotech (ONCY) Competitors $0.42 -0.01 (-2.02%) Closing price 04:00 PM EasternExtended Trading$0.43 +0.01 (+2.14%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCY vs. SLN, KRRO, ACRS, FATE, EPRX, IKT, GLSI, PLX, TARA, and FTLFShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Silence Therapeutics (SLN), Korro Bio (KRRO), Aclaris Therapeutics (ACRS), Fate Therapeutics (FATE), Eupraxia Pharmaceuticals (EPRX), Inhibikase Therapeutics (IKT), Greenwich LifeSciences (GLSI), Protalix BioTherapeutics (PLX), Protara Therapeutics (TARA), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. Oncolytics Biotech vs. Silence Therapeutics Korro Bio Aclaris Therapeutics Fate Therapeutics Eupraxia Pharmaceuticals Inhibikase Therapeutics Greenwich LifeSciences Protalix BioTherapeutics Protara Therapeutics FitLife Brands Oncolytics Biotech (NASDAQ:ONCY) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends. Do institutionals and insiders believe in ONCY or SLN? 6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media refer more to ONCY or SLN? In the previous week, Oncolytics Biotech had 6 more articles in the media than Silence Therapeutics. MarketBeat recorded 8 mentions for Oncolytics Biotech and 2 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.25 beat Oncolytics Biotech's score of 0.55 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncolytics Biotech 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ONCY or SLN? Oncolytics Biotech has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Silence Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Is ONCY or SLN more profitable? Oncolytics Biotech has a net margin of 0.00% compared to Silence Therapeutics' net margin of -342.00%. Silence Therapeutics' return on equity of -62.81% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Oncolytics BiotechN/A -141.15% -84.73% Silence Therapeutics -342.00%-62.81%-33.89% Does the MarketBeat Community believe in ONCY or SLN? Oncolytics Biotech received 116 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 78.95% of users gave Silence Therapeutics an outperform vote while only 68.51% of users gave Oncolytics Biotech an outperform vote. CompanyUnderperformOutperformOncolytics BiotechOutperform Votes16168.51% Underperform Votes7431.49% Silence TherapeuticsOutperform Votes4578.95% Underperform Votes1221.05% Do analysts rate ONCY or SLN? Oncolytics Biotech presently has a consensus target price of $4.33, suggesting a potential upside of 929.30%. Silence Therapeutics has a consensus target price of $33.83, suggesting a potential upside of 558.24%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Oncolytics Biotech is more favorable than Silence Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Silence Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has stronger earnings & valuation, ONCY or SLN? Oncolytics Biotech has higher earnings, but lower revenue than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncolytics BiotechN/AN/A-$20.56M-$0.29-1.45Silence Therapeutics$27.70M5.55-$53.82M-$1.50-3.43 SummarySilence Therapeutics beats Oncolytics Biotech on 9 of the 17 factors compared between the two stocks. Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCY vs. The Competition Export to ExcelMetricOncolytics BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.38M$6.49B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-1.568.9226.8419.71Price / SalesN/A253.79392.34117.39Price / CashN/A65.8538.2534.62Price / Book1.566.466.794.50Net Income-$20.56M$143.98M$3.23B$248.18M7 Day Performance-18.73%3.04%4.07%1.14%1 Month Performance-26.78%7.44%12.52%15.20%1 Year Performance-62.07%-2.46%16.83%6.56% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCYOncolytics Biotech1.7174 of 5 stars$0.42-2.0%$4.33+929.3%-61.6%$36.38MN/A-1.5630Earnings ReportAnalyst ForecastGap DownSLNSilence Therapeutics3.5301 of 5 stars$4.96+13.5%$33.83+582.1%-78.0%$148.45M$27.70M-3.16100Positive NewsKRROKorro Bio1.9902 of 5 stars$15.71+4.0%$102.43+552.0%-70.4%$147.53M$4.82M-1.6670Analyst RevisionGap DownACRSAclaris Therapeutics2.8746 of 5 stars$1.30-0.8%$10.00+669.2%+13.4%$140.77M$17.78M-2.50100Gap UpFATEFate Therapeutics4.3788 of 5 stars$1.22+14.0%$4.14+239.6%-68.0%$139.82M$13.34M-0.74550EPRXEupraxia Pharmaceuticals2.2192 of 5 stars$3.90+1.6%$10.50+169.2%+32.2%$139.81MN/A-5.4229Gap UpIKTInhibikase Therapeutics1.517 of 5 stars$1.87-7.0%$6.50+247.6%+7.0%$139.02M$260,000.00-0.706News CoverageGap DownGLSIGreenwich LifeSciences1.337 of 5 stars$10.18+4.5%$39.00+283.1%-21.3%$135.13MN/A-12.723Positive NewsEarnings ReportPLXProtalix BioTherapeutics2.1886 of 5 stars$1.68+0.6%$15.00+792.9%+43.3%$133.74M$59.76M-12.92200TARAProtara Therapeutics2.1936 of 5 stars$3.42+7.2%$20.40+496.5%+16.4%$131.95MN/A-1.2130Positive NewsGap UpFTLFFitLife Brands4.4273 of 5 stars$13.79+1.1%$20.50+48.7%+0.9%$129.41M$64.47M16.3220Earnings Report Related Companies and Tools Related Companies Silence Therapeutics Competitors Korro Bio Competitors Aclaris Therapeutics Competitors Fate Therapeutics Competitors Eupraxia Pharmaceuticals Competitors Inhibikase Therapeutics Competitors Greenwich LifeSciences Competitors Protalix BioTherapeutics Competitors Protara Therapeutics Competitors FitLife Brands Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCY) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
